Repeated sequences in CASPASE-5 and FANCD2 but not NF1 are targets for mutation in microsatellite-unstable acute leukemia/myelodysplastic syndrome

被引:18
作者
Offman, J
Gascoigne, K
Bristow, F
Macpherson, P
Bignami, M
Casorelli, I
Leone, G
Pagano, L
Sica, S
Halil, O
Cummins, D
Banner, NR
Karran, P [1 ]
机构
[1] Canc Res UK London Res Inst, Mammalian DNA Repair Lab, Clare Hall Labs, S Mimms EN6 3LD, Herts, England
[2] Ist Super Sanita, I-00161 Rome, Italy
[3] Catholic Univ, Dept Hematol, Rome, Italy
[4] Harefield Hosp, Harefield UB9 6JH, Middx, England
关键词
D O I
10.1158/1541-7786.MCR-04-0182
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Microsatellite instability (MSI) in tumors is diagnostic for inactive DNA mismatch repair. It is widespread among some tumor types, such as colorectal or endometrial carcinoma, but is rarely found in leukemia. Therapy-related acute myeloid leukemia/myelodysplastic syndrome (tAML/MDS) is an exception, and MSI is frequent in tAML/MDS following cancer chemotherapy or organ transplantation. The development of MSI+ tumors is associated with an accumulation of insertion/deletion mutations in repetitive sequences. These events can cause inactivating frameshifts or loss of expression of key growth control proteins. We examined established MSI+ cell lines and tAML/MDS cases for frameshift-like mutations of repetitive sequences in several genes that have known, or suspected, relevance to leukemia. CASPASE-5, an acknowledged frameshift target in MSI+ gastrointestinal tract tumors, was frequently mutated in MSI+ cell lines (67%) and in tAML/MDS (29%). Frameshiftlike mutations were also observed in the NF1 and FANCD2 genes that are associated with genetic conditions conferring a predisposition to leukemia. Both genes were frequent targets for mutation in MSI+ cell lines and colorectal carcinomas. FANCD2 mutations were also common in MSI+ tAML/MDS, although NF1 mutations were not observed. A novel FANCD2 polymorphism was also identified.
引用
收藏
页码:251 / 260
页数:10
相关论文
共 38 条
[1]   CLUES TO THE PATHOGENESIS OF FAMILIAL COLORECTAL-CANCER [J].
AALTONEN, LA ;
PELTOMAKI, P ;
LEACH, FS ;
SISTONEN, P ;
PYLKKANEN, L ;
MECKLIN, JP ;
JARVINEN, H ;
POWELL, SM ;
JEN, J ;
HAMILTON, SR ;
PETERSEN, GM ;
KINZLER, KW ;
VOGELSTEIN, B ;
DELACHAPELLE, A .
SCIENCE, 1993, 260 (5109) :812-816
[2]   Death pathway genes Fas (Apo-1/CD95) and Bik (Nbk) show no mutations in colorectal carcinomas [J].
Abdel-Rahman, WM ;
Arends, MJ ;
Wyllie, AH ;
Morris, RG ;
Ramadan, ME .
CELL DEATH AND DIFFERENTIATION, 1999, 6 (05) :387-388
[3]   Cancer in Fanconi anemia, 1927-2001 [J].
Alter, BP .
CANCER, 2003, 97 (02) :425-440
[4]   Fanconi anemia: Myelodysplasia as a predictor of outcome [J].
Alter, BP ;
Caruso, JP ;
Drachtman, RA ;
Uchida, T ;
Velagaleti, GVN ;
Elghetany, MT .
CANCER GENETICS AND CYTOGENETICS, 2000, 117 (02) :125-131
[5]  
BenYehuda D, 1996, BLOOD, V88, P4296
[6]   Mismatch repair and response to DNA-damaging antitumour therapies [J].
Bignami, M ;
Casorelli, I ;
Karran, P .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (15) :2142-2149
[7]   DEFECTIVE MISMATCH BINDING AND A MUTATOR PHENOTYPE IN CELLS TOLERANT TO DNA DAMAGE [J].
BRANCH, P ;
AQUILINA, G ;
BIGNAMI, M ;
KARRAN, P .
NATURE, 1993, 362 (6421) :652-654
[8]   Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells [J].
Branch, P ;
Masson, M ;
Aquilina, G ;
Bignami, M ;
Karran, P .
ONCOGENE, 2000, 19 (28) :3138-3145
[9]   Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome [J].
Casorelli, I ;
Offman, J ;
Mele, L ;
Pagano, L ;
Sica, S ;
D'Errico, M ;
Giannini, G ;
Leone, G ;
Bignami, M ;
Karran, P .
DNA REPAIR, 2003, 2 (05) :547-559
[10]   The Fanconi anaemia BRCA pathway [J].
D'Andrea, AD ;
Grompe, M .
NATURE REVIEWS CANCER, 2003, 3 (01) :23-34